The IGF-1/AKT/mTOR pathway is also one of the key targets for ES treatment and IGF receptor 1 (IGF-1R) and mTOR inhibitors prevent tumour growth and improve ES survival rate in a mouse xenograft model [95]. Here, AKT1 is linked to neoplasm.